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Occlusive arterial disease, including coronary heart disease (CHD) and peripheral arterial
disease (PAD), is the main cause of death, with an annual mortality incidence predicted
to rise to 23.3 million worldwide by 2030. Current revascularization techniques consist
of angioplasty, placement of a stent, or surgical bypass grafting. Autologous vessels,
such as the saphenous vein and internal thoracic artery, represent the gold standard
grafts for small-diameter vessels. However, they require invasive harvesting and are often
unavailable. Synthetic vascular grafts represent an alternative to autologous vessels.
These grafts have shown satisfactory long-term results for replacement of large- and
medium-diameter arteries, such as the carotid or common femoral artery, but have poor
patency rates when applied to small-diameter vessels, such as coronary arteries and
arteries below the knee. Considering the limitations of current vascular bypass conduits,
a tissue-engineered vascular graft (TEVG) with the ability to grow, remodel, and repair
in vivo presents a potential solution for the future of vascular surgery. Here, we review
the different methods that research groups have been investigating to create TEVGs in
the last decades. We focus on the techniques employed in the manufacturing process of
the grafts and categorize the approaches as scaffold-based (synthetic, natural, or hybrid)
or self-assembled (cell-sheet, microtissue aggregation and bioprinting). Moreover, we
highlight the attempts made so far to translate this new strategy from the bench to the
bedside.
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INTRODUCTION
Cardiovascular disease is the principal cause of death worldwide. Common manifestations
are coronary heart disease (CHD) and peripheral arterial disease (PAD), which develop as a
consequence of the critical atherosclerotic narrowing of supplying arteries. The worldwide annual
incidence of deaths related to cardiovascular disease, is expected to rise to 23.3 million by 2030
(Criqui and Aboyans, 2015). In the UK alone, more than 2 million people suffer from CHD.
Moreover, there are 188,000 hospital episodes attributed to a myocardial infarction (MI) each year.
Approximately 12 to 20% of people over the age of 60 develop PAD and many of them manifest
critical limb ischemia, which is associated with a poor quality of life and high risk of amputation
and death (Townsend et al., 2015).
Prompt restoration of tissue perfusion is pivotal for preventing heart failure in patients with
CHD and for helping the repair of ischemic limbs. Current revascularization techniques consist
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of angioplasty, placement of a stent, or surgical bypass grafting. In
the United States, an average of 400,000 coronary artery bypass
grafting (CABG) interventions are recorded annually (Epstein
et al., 2011; Pashneh-Tala et al., 2015). Moreover, the number of
invasive lower-extremity vascular procedures for patients with
PAD has doubled over the last decade. The surgical bypass
grafting mostly involves the use of autologous vessels, such
as the saphenous vein and internal thoracic artery. Though
representing the gold standard for small-diameter (<6mm)
vascular replacement, these vessels require invasive harvesting
and are often unsuitable for use. For instance, in patients needing
primary revascularization of the lower extremities, as many as
30% lack a suitable autogenous vein. This number increases to
50% in those patients requiring a secondary bypass procedure.
Furthermore, venous grafts can develop neointimal hyperplasia
in the peri-anastomotic regions. Patency rates for saphenous vein
grafting remain limited, with both coronary and femoro-popliteal
reconstructions showing failure rates of approximately 50% at 10
years (Goldman et al., 2004; van Dijk et al., 2007; Collins et al.,
2008; Kim et al., 2008; Schwann et al., 2009; Harskamp et al.,
2013).
Surgical revascularization with implantation of
conduits made of non-biodegradable polymers, including
Polytetrafluoroethylene (PTFE), Gore-Tex, and Dacron, prove
to be effective when replacing large vessels. However, when
used in the application of small-diameter vascular grafts, they
were complicated by the occurrence of thrombotic occlusions
(Jackson et al., 2000; van Det et al., 2009; Takagi et al., 2010).
Considering the limitations of current vascular bypass
conduits (Gui and Niklason, 2014), a tissue-engineered vascular
graft (TEVG) embedded with cells to generate a living material
capable of physiological remodeling represents a potential
solution for the future of vascular surgery. In this review, we
provide a summary of methodologies and solutions adopted in
recent years that aim to create functional small-diameter TEVGs.
TISSUE ENGINEERING
Halfway through the twentieth century, the first autologous
saphenous vein was used as a vascular graft in a clinical
application by Kunlin (1951). By the end of the 1970s, synthetic
material such as Dacron (De Bakey et al., 1958) and PTFE (Soyer
et al., 1972; Campbell et al., 1976; Tellis et al., 1979), were
introduced for aortic and lower extremity bypass, respectively.
As mentioned above, the low patency rate over a long period of
implantation was the common limitation of these vascular grafts.
Tissue engineering aims to provide alternative and innovative
solutions for small diameter vascular replacement, and an
interdisciplinary approach could offer the chance to design a graft
for any specific target tissue and clinical needs.
The first commercially available acellular TEVG from bovine
and human origin, such as Artegraft (North Brunswick, NJ)
(Hutchin et al., 1975), Procol (Hancock Jaffe Laboratories
Inc., Irvine, CA) (Hatzibaloglou et al., 2004), and Cryovein
(CryoLife, Kennesaw, GA) (Madden et al., 2004), appeared on
the market toward the end of the 1970s. Nevertheless, the
flourishing number of techniques and innovative approaches
finds its definitive turning point with Weinberg and Bell in
1986, who first tried to fabricate a biological vascular graft with
xenogenic cells embedded to circumvent the limited availability
of autologous cells (Weinberg and Bell, 1986). A collagen gel was
used as a substrate on which they cultured bovine fibroblasts,
vascular smooth muscle cells (VSMCs) and endothelial cells
(ECs), thereby recreating the adventitia, media and intima layers
of the vessel, respectively. This attempt led to the fabrication
of a vessel-like structure with poor mechanical properties, that
required a Dacron mesh to act as a structural support. Despite
its apparent failure, this pioneering study drew a new path
in TEVG development. From then on, many attempts have
been made, ultimately leading to a standardized set of quality
control criteria for TEVG fabrication, that is based on the
performance of the actual “gold standard” [for example the
saphenous vein (SV) or internal mammary artery (IMA)]. The
ideal TEVG, therefore, should have anti-thrombogenic properties
preferentially conferred by a fully autologous endothelium.
Another important quality requisite is the similarity of TEVG
mechanical properties to the native tissue, with a recommended
minimum burst pressure of 1700 mmHg (Konig et al., 2010; Wise
et al., 2011), together with a fatigue resistance of 30 days to cyclic
loading in vitro (L’Heureux et al., 2007) and a level of compliance
necessary to avoid excessive stress. A mechanical mismatch is
acknowledged as a key determinant in the loss of long-term
patency, resulting in aneurysm formation and implant at failure.
The living cell component within the TEVG is critical to provide
remodeling potential and biochemical signaling (G et al., 2015)
while being devoid of immunogenic activity. To achieve clinically
valuable outcomes, the manufacturing process has to take into
account other fundamental aspects, such as the capability of the
TEVG to be stored and delivered ready for the intervention as
well as to be easily manipulated during the implantation.
TEVGs can bemainly categorized into self-assembled vascular
grafts and scaffold-based approaches, using synthetic, natural
or hybrid materials. Natural polymers, can then be further
categorized into extracellular matrix (ECM)-based material and
decellularized natural matrices.
Scaffold-Based Tevgs
The scaffold-based approach represents the most diffuse strategy
to build TEVGs. The popularity of this methodology is justified
by the fact that the presence of physical support enables
the cells to follow a pathway during their colonization and
proliferation. As introduced previously, the study performed by
Weinberg and Bell pioneered the development of the scaffold-
based methodology which during the last 30 years, saw the
introduction of many variables and the use of a great variety of
manufacturing techniques and materials.
Synthetic Materials
Synthetic polymers have been widely used for the fabrication of
TEVGs. The advantage is that the final properties of the graft
can be tuned to meet the clinical needs, choosing the appropriate
fabrication technique and specific material. However, the
required higher level of technologies and the long period
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involved in the process of manufacturing constitute significant
obstacles to clinical translation. Other prominant disadvantages
shown by these materials are the lack of cell binding sites and
the necessity to ensure an anti-thrombogenic property of the
lumen, as required in the case of PLGA. A variety of polymers
and copolymers have been tested. The most studied comprise
degradable polyesters, like polyglycolic acid (PGA) (Niklason and
Langer, 1997; Hoerstrup et al., 2006), poly-lactic acid (PLA),
poly-l-lactic acid (PLLA) (Yokota et al., 2008), their copolymer
poly (lactide-co-glycolide) (PLGA) (In Jeong et al., 2007),
and polycaprolactone. Among the biodegradable polymers,
polyurethanes (PU) (Hashi et al., 2007; Nieponice et al., 2010;
Sharifpoor et al., 2011) and Poly(glycerol-sebacate) (PGS) (Wu
et al., 2012), which are bioabsorbable elastomers, possess good
biocompatibility properties allowing proliferation of endothelial
cells (ECs) onto the luminal side and parietal infiltration of
VSMCs (Gao et al., 2006; Rai et al., 2012). Hemocompatibility
testing sees PGS having a low platelet adhesion and inflammation
(Motlagh et al., 2006) and stimulating the production of elastin
(Lee et al., 2011). However, the main issue was represented
by the lack of mechanical properties, with a burst pressure of
200 mmHg (Lee et al., 2011). Various TEVG models fabricated
with synthetic polymers have been assessed in preclinical small
and large animal models. Both PU (Nieponice et al., 2010)
seeded with mouse-derived MSCs and bone marrow-derived
stem cells (BMDSCs) seeded onto PLA (Hashi et al., 2007)
vascular grafts were used in a rat model and showed patency
rates of 50 and 100% respectively, after several weeks from
implantation. PGA is the most extensively explored material
having been used in sheep (Brennan et al., 2008; Cummings
et al., 2012), dogs, pigs (Quint et al., 2011) and primate
models. Acellular electrospun PCL conduits, implanted into a
mouse carotid model, allowed complete endothelium formation
in 28 days. However, neointimal formation was detected, in
particular at the anastomoses (Chan et al., 2017). Electrospinning
microfabrication technique is often used to generate tubular
structures composed of nanofibers from different polymers.
Composite scaffolds made of PCL/poly(ethylene oxide) (Wang
et al., 2016) and PCL/PLGA (Ong et al., 2017) have been tested
in animal models with the later acellular graft having been
evaluated in an ovine bilateral arteriovenous shunt model. Such
a model showed good results in term of patency (66%) and
endothelialization of the lumen after 4 weeks of implantation, but
the graft eventually dilated as a consequence of inadequate elastin
content (Ong et al., 2017).
Despite the great variety of preclinical studies, very few
assessed the clinical utility of this type of TEVGs. One key study
involving synthetic biodegradable polymers has been carried out
by Niklason et al. using PGA seeded with VSMCs to create a
small diameter TEVG (Niklason and Langer, 1997). The graft
was conditioned with pulsatile flow for 8 weeks to achieve
full maturation, through deposition of collagen matrix. At the
end of the in vitro culturing, the structure showed a burst
pressure of 2150 mmHg (Niklason, 1999; Niklason et al., 2001).
These engineered blood vessels, named Humacyte (Humacyte
Incorporated, RTP, NC), were tested in a series of small and
large animals models, showing 100% patency after 24 days and
88% after 6 months in dogs and baboons, respectively (Dahl
et al., 2011, 2013). These promising results led to a clinical trial
that got underway in 2012, in which the acellular PGA scaffolds
were used for vascular access in patients with end-stage renal
disease (Gui and Niklason, 2014; Lawson et al., 2016). This
study involved 60 patients recruited in Poland and the US with
an average of follow-up period of 16 months, during which 4
patients died, although none were associated with the failure of
the graft (Lawson et al., 2016) (Table 1). Additionally no immune
response or aneurysm formation was detected. In term of efficacy,
the TEVGs were successfully patent (63%) at 6 months, while
the patency rate dropped to 28% after 12 months. This led to
numerous interventions of thrombectomy to restore the patency
(Lawson et al., 2016).
Natural Materials
ECM based grafts
The lack of bio-activity of synthetic scaffolds prompted
researchers to investigate natural polymers obtained from ECM
as a possible alternative option. Proteins derived from the ECM
have the benefit of maintaining the natural binding sites for cell
adhesion, improving biomimetic and biocompatibility properties
of the material and stimulating the colonization and proliferation
of recruited cells. Collagen, gelatin, elastin, fibrin, and silk-
fibroin are the most extensively used in tissue engineering.
Different manufacturing techniques can be selected to produce
a TEVG of this kind. Typical fabrications procedures consist
of electrospinning (Soffer et al., 2008), freeze-drying (Engbers-
Buijtenhuijs et al., 2006; Zhang et al., 2006), and mold casting
(Boccafoschi et al., 2007; Schutte et al., 2010) (Figure 1C).
Electrospun meshes of gelatin (Elsayed et al., 2016) have been
used, usually in combination with a polymeric structure, to
improve the surface conjugation with cells, while silk-fibroin
nanofibers tubes have been used alone (Marelli et al., 2010) or as
a support matrix for coating hydrogel such as collagen (Marelli
et al., 2012) and gelatin (Marcolin et al., 2017). The feasibility of
the approach has been proven in vitro, with the tubular scaffold
showing encouraging mechanical properties (burst pressure of
1075± 444 mmHg) (Marcolin et al., 2017).
Following the Weinberg and Bell study in 1986, most of
the studies focusing on natural materials have used a gel-based
approach. This consists of casting a mixture of the desired gel and
cell suspension in a tubular mold made of a polypropylene tube.
The first period of incubation and cell growth is followed by a
period of maturation in dynamic conditions to confer properties
of a vascular tissue (Weinberg and Bell, 1986). Tranquillo et al.
achieved the fabrication of a tubular structure using a fibrin gel
with human dermal fibroblasts, but the burst pressure after 3
weeks was still far below (543 mmHg) the SV values (Huynh
and Tranquillo, 2010). Natural gels, based on collagen and fibrin,
have been evaluated as a possible artificial arterial conduit in
animal models. The above mentioned fibrin-based structure
with fibroblasts was implanted into the femoral artery of sheep.
Cyclic deformation in addition to pulsatile flow conditioning
improved mechanical properties of the graft (Syedain et al.,
2011). To further improve the mechanical properties of the
TEVG, a suspension of ovine dermal fibroblasts were added to
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TABLE 1 | TEVG applied in human studies.
Approaches Applications Scaffold materials and fabrication
methods
Groups
Natural material-based TEVG Graft as an extrahepatic portal vein bypass. Decellularized human iliac vein seeded with
autologous cells
No commercial product
Sumitran-Holgersson and colleagues
(Olausson et al., 2012)
Lower extremity bypass surgery Decellularized bovine carotid artery graft
Commercial name:
Artegraft, (North Brunswick, NJ)
Lin and colleagues (Lindsey et al., 2017)
Synthetic material-based TEVG Arteriovenous (AV) shunt for heamodyalisis Decellularization of PGA scaffolds seeded with
cadaver SMCs.
Commercial name:
Humacyte, (Humacyte Incorporated, RTP, NC)
Dahl/Niklason and colleagues (Lawson
et al., 2016)
Self-assembled TEVG AV shunt for heamodyalisis access Cell-sheet of human fibroblast in a shape of
conduit. ECs were seeded in the graft after
devitalization of the luminal side.
Commercial name:
Cytograft, (Cytograft Tissue Engineering, Inc.)
L’Heureux and colleagues (Wystrychowski
et al., 2011)
AV shunts for hemodialysis access Cell-sheet of human fibroblast in a shape of
conduit, without further endothelialization.
Dehydrated and stored (−80◦C) before clinical
application.
Commercial name:
LifeLineTM, (Cytograft Tissue Engineering, Inc.)
L’Heureux and colleagues (Wystrychowski
et al., 2014)
the fibrin and the gelled structure was cultured for a total period
of 5 weeks (the first 2 in static conditions and the remaining 3
under pulsatile flow stimulation) (Syedain et al., 2014). At the
end of the conditioning period, the structure was decellularized.
This process led to obtaining a TEVG with around 4200 mmHg
burst pressure, able to remain patent for 24 weeks and with a
concentration of collagen and elastin close to the natural values
(Syedain et al., 2014). In another study, VSMCs were used to
colonialize the fibrin gel and ECs were seeded on to the luminal
side before implantation into an ovine model (Swartz, 2004;
Liu et al., 2007). This graft showed good results in terms of
integration with the native vessel but, on the other hand, it
displayed poor mechanical properties.
Silk fibroin-based materials were considered as an alternative
(Enomoto et al., 2010) and Kaplan et al. implanted a graft of
this kind in the abdominal aorta of rats (Lovett et al., 2010).
No thrombosis was seen and implants remained patent, with
the absence of occlusion or ischemia detected at the 1 month
follow-up.
Collagen-based vascular grafts were recently tested in vivo and
assessed for the feasibility of the system to hold microsurgical
sutures. Dehydration of crosslinked collagen allowed to create
a small-diameter TEVG (diameter ≤ 1mm) with a burst
pressure of approximately 1313 mmHg, compliance of 1.7%/100
mmHg (comparable with mammalian vein), but the strength
of the anastomosis at the interface between the rat femoral
artery and TEVG was still lower than the one between two
portions of explanted rat femoral artery (Li et al., 2017).
Natural polymers are acknowledged to be valid alternatives in
the production of small diameter TEVGs, due to their higher
biocompatibility and capability to remodel in vivo. Nonetheless,
natural polymers generally offer reduced mechanical strength
compared to their synthetic counterparts and can be more
susceptible to degradation, which, if not carefully controlled, may
lead to rupture and aneurysm formation.
Decellularized natural matrices
The mismatch of mechanical properties, in terms of strength,
elasticity, long-term resistance, and fatigue, between the
fabricated scaffold and the native vessel led to development of
grafts with a structure more similar to the biological ones, but
available as an off-the-shelf product. This need was reflected by
further attempts to employ decellularization of tissues harvested
from allogenic or xenogeneic sources (Figure 1). The elimination
of cells is needed to avoid an immunological reaction from
the recipient, but agents employed to this scope should have
properties allowing preservation of the structure and function
of the ECM. These techniques typically use detergents, like
sodium dodecyl sulfate, octylglucoside, sodium deoxycholate,
and enzymes, like dispase II, nucleases, phospholipase, and
thermolysin, often in combination with mechanical and physical
methods to accelerate the process (Crapo et al., 2011).
The approach based on natural matrices to obviate the
problems associated with autologous grafts, led to the
commercialization of a variety of decellularized products,
such as Procol (Hancock Jaffe Laboratories Inc., Irvine, CA),
the SG 100 SynerGraft R© vascular graft, (CryoLife, Kennesaw,
Georgia, USA) and the already mentioned Artegraft (North
Brunswick, NJ). To improve the properties of these grafts,
autologous ECs and VSMCs obtained from differentiation
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FIGURE 1 | Schematic illustration of TEVG manufacturing process. (A,B) Tissues obtained from biopsies of patients are treated and cells are isolated and expanded
in vitro. (C) Microfabrication techniques, such as freeze-drying and electrospinning, can be used to treat natural and synthetic materials in order to obtain a porous
scaffold. Another approach sees the casting of a suspension of gel and cells into a mold to produce a tubular structure. Vascular and non-vascular tissues, obtained
from allogeneic or xenogeneic sources, are used as TEVGs after being decellularized by using detergents and enzymes. (D) The TEVG undergoes cellularization with
the expanded autologous cells before moving to dynamic conditioning into bioreactor which allows the maturation of the structure. (E) The manufactured TEVG is
implanted into the patient.
of bone marrow-derived cells were seeded in decellularized
matrices and then tested in ovine (Tillman et al., 2012) and
canine models (Cho et al., 2005).
Decellularized vascular grafts derived from bovine have been
widely experimented in clinical trials (Katzman et al., 2005;
Chemla and Morsy, 2009) in which their performance was
compared with the classical PTFE graft in arteriovenous fistula
(AVF) and bypass procedures (Butler et al., 1977). Despite
the investments, the grafts maintained high costs, showed low
patency and multiple cases of immunogenic response due to the
inefficacy in the decellularization process. Sumitran-Holgersson
et al. performed the first human study on a single pediatric
patient (Table 1), using a decellularized human iliac vein seeded
with autologous cells (Olausson et al., 2012). The outcomes were
promising, with patency up to 2 years even if applied in a low-
flow district. A recent long-term study (2002–2017) showed the
application of a bovine carotid artery graft (Artegraft) in lower
extremity bypass surgery (Lindsey et al., 2017). Follow-up of 5
years of primary endpoints showed positive results for patency
(66.7%) and salvage limb rates (81% of treated cases) (Table 1).
Among the non-vascular tissues, swine or bovine pericardium
have been tested in the past, but porcine small intestinal
submucosa (SIS) was the first to be assessed as a valid tissue
source (Sandusky et al., 1995). SIS, used as an arteriovenous
shunt in a sheep model, showed burst pressure of around
1200 mmHg and the cellularization of the graft improved the
anticoagulation properties with a lower rate of platelet aggregate
formation (Peng et al., 2011). The decellularization process has
many disadvantages. In fact, the main cause of failure is related
to immune response induced by leftovers of foreign cellular
material. Although the biological origin of the tissue reduced
the gap between the properties of the native vessel and the built
graft, a persistent limitation consists of the divergent behavior
under long-term stress. This difference leads to failure of the graft
and possible creation of an aneurysm. In addition, decellularized
grafts originating from non-vascular tissue, even if more reliable,
are unsuitable for applications in which the scaffold has the
necessity to adapt and grow with the patient, as in the case
of correction of congenital vascular defects. In these patients,
atherosclerotic and fibrotic remodeling and calcification are the
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most common consequences of poor integration of the graft with
the surrounding tissue, resulting in stenosis and graft failure and
requiring multiple interventions for substitution (Shetty et al.,
2009; Gössl et al., 2012; Woo et al., 2016).
Hybrid Scaffolds
Natural and synthetic polymers can be used together to create
a composite scaffold in order to improve the characteristics that
each category possess on its own. In recent years, initially positive
results led to investment in this approach. A three-layered TEVG
has been fabricated overlapping nanofibers of PCL, collagen, and
PLLA (Haghjooy Javanmard et al., 2016). PCL has also been
used blended with collagen (Tillman et al., 2009; Bertram et al.,
2017), gelatin (Jiang et al., 2017) and elastin (Wise et al., 2011) to
improve surface adhesion features, while a PLCL porous scaffold
was coated with nanofibers of silk fibroin (Henry et al., 2017)
or alternatively with a layer of hMSCs/ECs (Ahn et al., 2015;
Pangesty et al., 2017).
PEG-fibrin hydrogel, with murine smooth muscle progenitor
cells, was reinforced with an inner layer of electrospun PU fibers
(McMahon et al., 2011). in vivo experiments with composite
TEVGs were performed in the last decade demonstrating the
feasibility of the hybrid approach. Murine models have been used
to evaluate TEVGs composed of nanofibers of PCL blended with
spider silk and chitosan (Zhao et al., 2013), and the scaffold
showed maintenance of the patency for up to 8 weeks. A more
recent experiment involved a decellularized rat aortic vessel in
which the lumen was coated with heparin. Aiming at preventing
the vessel weakening and consequent aneurysm formation, the
decellularized structure was externally reinforced with PCL
(Gong et al., 2016). This hybrid scaffold was easily sutured
and displayed improved mechanical properties compared to rat
autografts, with a burst pressure of 2060 mmHg and patency rate
of 100% after 10 weeks implantation. In a large animal model,
Poly(L/D)lactide (P(L/DL)LA) coated with fibrin gel was used as
an interposed carotid artery graft in sheep (Koch et al., 2010).
Autologous ECs, VSMCs, and fibroblasts were encapsulated in
the fibrin gel and cast around the synthetic polymer before the
bioreactor conditioning for 21 days to allow for the maturation
of the cells. The TEVG was then implanted and after 6
months it showed the absence of thrombus and full patency.
A study was recently performed on a large animal, grafting a
PCL/collagen scaffold seeded with autologous ECs and VSMCs
as arterial interposition. Computed tomography (CT) scan and
ultrasonography showed no stenosis and structural integrity of
the TEVG at 6 months follow-up (Ju et al., 2017). Though the
hybrid approach offers an opportunity of exploiting the qualities
of natural and synthetic polymers, a typical drawback is a need
for long conditioning and the requirement of high technological
skills during the manufacturing process.
Self-Assembled Tevg
Despite the improvements achieved in fabricating TEVGs based
on scaffolds, some research groups believed that scaffolds would
force the cells to grow in an unnatural assembly, and therefore
decided to test the tissue engineered self-assembled (TESA)
approach. Self-assembled TEVGs are based on the concept
that cells, placed in a 3D environment and with the right
stimuli, would be able to organize themselves in a complex
tissue. Currently, three main strategies have been investigated:
cell-sheet assembly, micro-tissue aggregation, and cell printing
(Figure 2). Different cell sources have been considered suitable
to generate a cell-sheet tissue engineered graft. Human adipose-
derived stromal cells (Vallières et al., 2015) and dermal or SV
fibroblasts (Bourget et al., 2012) were used to create a scaffold-
free graft and, after in vitro characterization, displayed good
mechanical properties and the ability to produce ECM proteins,
including collagen type I, III, and IV, laminin and fibronectin,
which are necessary to give structural support to the vessel.
The development of this novel scaffold-free approach finds its
origin in the success of the first trial by the pioneer L’Heureux.
In 1998, L’Heureux et al. first documented the feasibility of
implanting a cell-sheet graft in a canine model (L’Heureux et al.,
1998). The technique consisted of peeling off a confluent culture
of VSMCs and fibroblasts and carefully shaping the cell sheet
with all the released ECM into a tubular structure (Figure 2A).
Conditioning in a bioreactor represents a crucial step to allow the
maturation of the cells by fusion of the wrapped layers in a unique
vascular structure. After the extended conditioning (8 weeks)
under dynamic conditions, the graft showed a burst pressure of
around 2600 mmHg, which is higher than that of SV. Relevant
to the physiological maturation of the graft, the authors showed
the production of ECM proteins typical of the vasculature and
the recruitment of ECs onto the luminal surface. Nonetheless,
at 7 days post-implantation, the grafts exhibited bleeding and
detachment of the layers leading to the failure of the implant.
To overcome these limitations, a new study to fabricate scaffold-
free TEVGs was performed, involving only human fibroblasts
and increasing the period in dynamic culture (L’Heureux et al.,
2006). The new grafts showed greater performances from the
point of view of mechanical properties (burst pressure of 3468
mmHg) and were used as an arterial interposition in primate
models. The grafts were shown to be resistant, did not form
aneurysms and were fully patent after 8 weeks. Overall, the main
limitation of the technique is the time to produce the graft which,
considering the duration between the formation of a confluent
sheet and the fusion throughout the bioreactor conditioning,
was assessed to be around 28 weeks (L’Heureux et al., 2006).
Scaffold-free grafts, containing autologous mesenchymal stem
cells (MSCs), were tested by Zhao et al. during pre-clinical studies
in a rabbit model (Zhao et al., 2012). The TEVG, used to replace
a section of carotid artery 1 cm in length, was fully patent and
completely endothelialized after the 4 weeks from implantation.
An assessment of histology showed a full integration of the cell-
sheet graft and a more complex remodeling in the laminated
structure after the period of implantation.
In the meantime, the scaffold-free engineered graft developed
by L’Heureux et al., patented with the name of Cytograft
(Cytograft Tissue Engineering, Inc., Novato, CA), was used at the
beginning of the 2000s in a clinical trial involving 10 patients
that suffered from end-stage renal disease (McAllister et al.,
2009). Fibroblasts obtained from biopsies of the patient were
used to create the autologous TEVG. The fabrication procedure,
illustrated above, was completed with the devitalization of the
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luminal side of the graft, and subsequent seeding of autologous
ECs. The period of time required to produce these grafts turned
out to be around 7.5 months. Excluding one patient that died for
a cause not related to the graft, the other 3 failures of the self-
assembled blood vessel were related to dilatation, thrombosis,
and aneurysms. After the 20 month trial, the overall results of
the study were promising. Grafts had 78% patency rate at the
time point of 1 month and 60% at 6 months. In this study,
McAllister et al. demonstrated the feasibility of long distance graft
delivery after fabrication in insulated and sealed conditions for
long distance (McAllister et al., 2009). L’Heureux’s group further
improved the production of an off-the-shelf graft attempting to
define a procedure to store the graft after the manufacturing
process. The cell-sheet based scaffolds were devitalized to be
frozen and at the moment in which the patient required the
implantation they were thawed, rehydrated and autologous
ECs were finally seeded on the luminal side (Wystrychowski
et al., 2011). The new allogenic LifelineTM (Cytograft Tissue
Engineering, Inc.), without the seeding of the autologous ECs,
was also used in patients as shunts for hemodialysis (Table 1).
The mechanical properties of the graft were not affected by
the thawing procedure and no immune response was detected
(Wystrychowski et al., 2014).
Microtissue aggregation represents a variation among the
TESA strategies, in which, to circumvent mechanical stress,
the cells are not peeled from the culture surface and the
post-culturing manipulation to shape the graft is avoided
using a growing template. In this approach, a temperature–
responsive poly(N-isopropylacrylamide) is used as culturing
surface, allowing the easy detachment of the cell aggregate when
the culture is confluent (Asakawa et al., 2010). Alternatively,
high density hanging drop cells are deposited in the mold for in
situ merging by secretion of ECM, representing building blocks
for vascular-like structures (Marga et al., 2012). Kelm et al.
obtained a tubular structure by the aggregation of human artery-
derived fibroblasts and HUVECs (Kelm et al., 2010) (Figure 2B).
Fourteen days of conditioning with dynamic pulsatile flow
allowed the fusion of the multiple blocks in a unique tissue with
layered tissue formation.
One typical constraint of the TESA technique is the limited
shape that the graft can assume. In fact, the inability of the
cell aggregation to self-sustain, forced the researcher to keep
the geometry as simple as possible. The possibility to rectify
this limitation was recently proposed by the use of Bioprinting,
which may have the refined capability to build a patient-specific
arterial vessel (Figure 2C). Bioprinting is currently used to
create constructs for growth factor delivery (Gao et al., 2015),
in vitro microvacularized constructs (Kamei et al., 2006; Cui
and Boland, 2009; Miller et al., 2012; Bertassoni et al., 2014;
Kolesky et al., 2014; Gao et al., 2015) and myocardial patches
(Gaebel et al., 2011; Gaetani et al., 2012, 2015). Some studies
have focused on providing a proof-of-concept for manufacturing
vascular structures with the intention to be used as small-
diameter TEVGs (Borovjagin et al., 2017; Duan, 2017). A novel
approach exploited the concept of self-assembly through the
fusion of cell spheroids forming a unique tubular structure
(Mironov et al., 2009). Norette et al. performed an initial study
attempting to bioprint a complex vascular tree (Norotte, 2009).
The high flexibility of this approach allowed the fabrication of
tubular structures by aggregation of spheroids, with connected
branches of accurate diameter and wall thickness. On the other
hand, this strategy showed limitations in terms of sterility
and its time-consuming nature. Maintaining the integrity of
the environment during the assembling of the vascular tree is
challenging, and a minimum of 7 days is required to allow
for the fusion of the spheroids on to the tubular surface. To
overcome some of these disadvantages, Norette et al. reduced
the complexity of the system and succeeded in the creation
of a tubular structure by deposition of human umbilical vein
VSMCs and skin fibroblasts (Norotte, 2009). Additionally, mouse
embryonic fibroblasts have been used by Kucukgul et al. to
fabricate a scaffold-free arterial construct (Kucukgul et al.,
2015). A bioprinted vascular graft suitable for implantation
and delivery to any large in vivo model or clinical trial has
not been developed, mainly due to the lack of mechanical
properties and the long period required to produce a stable
structure.
CONCLUSIONS
The necessity to find an alternative to autologous vascular
grafts led to the development of TEVG, which, exploiting the
combination of multiple approaches, holds promise to match
the minimal requirement of current autologous vessels. Many
improvements have been awarded in the recent past and
results from in vivo experiments showed encouraging outcomes.
Nevertheless, initial clinical trials did not always confirm the
experimental findings, thus suggesting there is still room for
improvements in the translational process.
Failure of TEVG could occur at different time points after the
implantation and, accordingly, can be classified as early, midterm
and late failures (Pashneh-Tala et al., 2015). Acute thrombosis
is the main cause of early failure (within 3 months after
implantation) and it is a coagulation reaction driven by platelet
adhesion on collagen, which in the native vasculature is avoided
by the anti-thrombotic properties of the endothelium. Acellular
and decellularized TEVGs are mostly affected by this issue.
Biodegradable TEVGs, cellularized or based on hybrid approach,
shielding the scaffold lumen from the bloodstream, show a
reduction in thrombus events. Multiple solutions have been
explored, combining different synthetic and natural materials
and performing chemical functionalization of the surface to
improve anti-thrombogenic properties (Seifu et al., 2013; Tara
et al., 2014). Furthermore, biodegradable polymers offer the
possibility for the cells to colonialize the porous structure and
thereby stimulate the production of ECM proteins. On the other
hand, if the properties of the polymers are not well tuned,
the intimal thickening can reduce the patency caused by the
excessive migration and proliferation of cells. Lumen occlusion
due to anastomotic intimal hyperplasia typically characterizes
the midterm failures (from 3 months to 2 years). Late term
failure is associated, instead, to recurrent atherosclerotic disease
and is a common problem with all the current approaches. It is
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FIGURE 2 | Schematic representation of techniques to manufacture scaffold-free vascular grafts. (A) Cell-sheet TEVG approach involves the use of a dense and
cohesive sheet of cells to create a tubular structure. The sheet is rolled around a mandrel and matured under dynamic conditions to develop vessel-like properties. (B)
Hanging drop cells are accurately positioned into a mold in the microtissue aggregation approach (B). The production of ECM allows the merging of the aggregates in
a complex structure. (C) Bioprinting exploits the extrusion of support material to increase the flexibility of the fabrication. An accurate design of support material and
cells extruded in spheroids allows the creation of tubular structures.
mainly due to the loss in consistency of the graft or poor in vivo
integration.
So far, decellularized native tissues are the most successful
in vivo approach, although post-implantation thrombus
events are the main limitation for low long-term patency.
Moreover, decellularization is still a topic of debate because the
incompleteness of the process may lead to an immunogenic
reaction by the recipient, whereas an excessive chemical
treatment can provoke the loss of mechanical properties and
aneurysmal dilatation (Shojaee and Bashur, 2017).
On the other hand, recent improvements in biodegradable
TEVG production, offering a wider range of physical properties
and the capability to remodel in vivo, might represent a potential
solution to generate a valid TEVG. New microfabrication
technologies allow patient-specific manufacturing of the TEVG,
eliminating the dimension mismatch at the anastomosis site.
This approach is particularly suitable for correction of congenital
related diseases. Nevertheless, patency rate is still drastically
lower than autologous grafts, with in vivo animal experiments no
longer than 2 years.
For the category of cellularized TEVGs, the cell source
represents a much discussed topic. As described in this review,
an extensive variety of cells have been tested, both to build the
core of the graft (in the case of a scaffold-free approach) and to
cellularize the scaffold in the pre-implantation stage. Autologous
mature vascular cells, like VSMCs, ECs, and fibroblasts, have
been used to cellularize TEVGs with success. Here, the main
limitation is represented by the extraction from a patient
biopsy, thereby leading to insufficient expansion (G et al.,
2015). Adult stem cells, such as BM-MSCs have been used in
consideration of their high proliferative property. The time-
consuming process of fabrication, cellularization or chemical
treatment is often not compatible with the urgent need of patients
suffering severe pathology. This can only be solved through
the adoption of an off-the-shelf TEVGs. In this approach,
standardization of the fabrication process, preservation of
sterile conditions and delivery represent the main challenges.
However, the potential of having a ready to use graft, with
advantages for patients and clinicians, is becoming an attracting
prospective.
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Owing to the growing target-population for tissue engineering
technologies/products under development for cardiac and
vascular indications, as well as the major healthcare costs
associated with existing treatments, the potential financial
figure for these products is in the range of multibillion-
dollar volume. In the U.S. alone, the total potential market
for tissue engineering and cell transplantation technologies
is expected to exceed USD 22.8 billion in the year 2019.
Furthermore, the global vascular graft market is expected to
reach USD 3,626 million by 2022, according to a new study
by Grand View Research, Inc. There is a positive prospect
that rising healthcare expenditure, favorable reimbursement
policies, and technological breakthroughs will boost growth in
the vascular graft market over the next 10 years. At present,
TEVGs contribute a minimal part of these financial figures,
however, a number of positive factors indicate that this new
technology will be successfully translated from research into
medical practice.
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